MX2021012336A - Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos. - Google Patents
Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos.Info
- Publication number
- MX2021012336A MX2021012336A MX2021012336A MX2021012336A MX2021012336A MX 2021012336 A MX2021012336 A MX 2021012336A MX 2021012336 A MX2021012336 A MX 2021012336A MX 2021012336 A MX2021012336 A MX 2021012336A MX 2021012336 A MX2021012336 A MX 2021012336A
- Authority
- MX
- Mexico
- Prior art keywords
- dll3
- car
- chimeric antigen
- antigen receptors
- humanized anti
- Prior art date
Links
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 title abstract 3
- 102100036466 Delta-like protein 3 Human genes 0.000 abstract 4
- 101000928513 Homo sapiens Delta-like protein 3 Proteins 0.000 abstract 4
- 229940127276 delta-like ligand 3 Drugs 0.000 abstract 4
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/7051—T-cell receptor (TcR)-CD3 complex
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/461—Cellular immunotherapy characterised by the cell type used
- A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/463—Cellular immunotherapy characterised by recombinant expression
- A61K39/4631—Chimeric Antigen Receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/46—Cellular immunotherapy
- A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
- A61K39/4643—Vertebrate antigens
- A61K39/4644—Cancer antigens
- A61K39/464402—Receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0646—Natural killers cells [NK], NKT cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
- C07K2317/53—Hinge
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Zoology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Mycology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Oncology (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Diabetes (AREA)
- Developmental Biology & Embryology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Se describen receptores de antígeno quimérico (CAR) específicos para DLL3, vectores que codifican el DLL3 CAR, células hospederas recombinantes que comprenden el DLL3 CAR (CAR-T o CAR-NK), y métodos para usar los CAR-T o CAR-NK para tratar una enfermedad asociada con la expresión de DLL3 de los mismos como se describe.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962830598P | 2019-04-08 | 2019-04-08 | |
US201962861377P | 2019-06-14 | 2019-06-14 | |
US201962896790P | 2019-09-06 | 2019-09-06 | |
US201962928615P | 2019-10-31 | 2019-10-31 | |
PCT/US2020/025643 WO2020210067A1 (en) | 2019-04-08 | 2020-03-30 | Humanized anti-dll3 chimeric antigen receptors and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2021012336A true MX2021012336A (es) | 2021-11-12 |
Family
ID=72750831
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2021012336A MX2021012336A (es) | 2019-04-08 | 2020-03-30 | Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos. |
Country Status (12)
Country | Link |
---|---|
US (1) | US20220184127A1 (es) |
EP (1) | EP3952888A1 (es) |
JP (1) | JP2022526420A (es) |
KR (1) | KR20210150432A (es) |
CN (1) | CN113795262A (es) |
AU (1) | AU2020271012A1 (es) |
BR (1) | BR112021016272A2 (es) |
CA (1) | CA3132202A1 (es) |
IL (1) | IL286984A (es) |
MX (1) | MX2021012336A (es) |
SG (1) | SG11202108759SA (es) |
WO (1) | WO2020210067A1 (es) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102509648B1 (ko) * | 2019-08-06 | 2023-03-15 | 아프리노이아 테라퓨틱스 리미티드 | 병리학적 타우 종에 결합하는 항체 및 이의 용도 |
TW202302650A (zh) * | 2021-05-08 | 2023-01-16 | 大陸商上海齊魯製藥研究中心有限公司 | 針對dll3的結合分子及其應用 |
CN114790240B (zh) * | 2022-06-10 | 2023-06-06 | 郑州大学 | SARS-CoV-2中和性单克隆抗体及应用 |
WO2024044779A2 (en) * | 2022-08-26 | 2024-02-29 | Juno Therapeutics, Inc. | Antibodies and chimeric antigen receptors specific for delta-like ligand 3 (dll3) |
CN116813784B (zh) * | 2023-05-17 | 2024-03-01 | 星奕昂(上海)生物科技有限公司 | 靶向dll3的抗体及其应用 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2069403B1 (en) * | 2006-10-02 | 2014-05-07 | Regeneron Pharmaceuticals, Inc. | High affinity human antibodies to human il-4 receptor |
US20120195831A1 (en) * | 2009-10-09 | 2012-08-02 | Ningyan Zhang | Generation, characterization and uses thereof of anti-her3 antibodies |
PT3342786T (pt) * | 2010-01-29 | 2021-09-24 | Chugai Pharmaceutical Co Ltd | Anticorpo anti-dll3 |
AU2011256290B2 (en) * | 2010-05-17 | 2014-06-12 | The Board Of Regents Of The University Of Texas System | Rapid isolation of monoclonal antibodies from animals |
WO2012019061A2 (en) * | 2010-08-05 | 2012-02-09 | Stem Centrx, Inc. | Novel effectors and methods of use |
CA2842281A1 (en) * | 2011-08-05 | 2013-02-14 | Ifom Fondazione Istituto Firc Di Oncologia Molecolare | Constitutively active upar variants and their use for the generation and isolation of inhibitory antibodies |
SG10201806867VA (en) * | 2012-02-24 | 2018-09-27 | Abbvie Stemcentrx Llc | Dll3 modulators and methods of use |
CN103173413A (zh) * | 2012-12-07 | 2013-06-26 | 天津三箭生物技术有限公司 | 小鼠抗人β-Catenin单克隆抗体及分泌该单克隆抗体的杂交瘤细胞株 |
GB201302447D0 (en) * | 2013-02-12 | 2013-03-27 | Oxford Biotherapeutics Ltd | Therapeutic and diagnostic target |
US9879087B2 (en) * | 2014-11-12 | 2018-01-30 | Siamab Therapeutics, Inc. | Glycan-interacting compounds and methods of use |
MA41613A (fr) * | 2015-02-23 | 2018-01-02 | Abbvie Stemcentrx Llc | Récepteurs antigéniques chimériques anti-dll3 et procédés d'utilisation desdits récepteurs |
TWI793062B (zh) * | 2015-07-31 | 2023-02-21 | 德商安美基研究(慕尼黑)公司 | Dll3及cd3抗體構築體 |
EA202090839A1 (ru) * | 2017-09-27 | 2021-02-04 | Юниверсити Оф Саутерн Калифорния | Новые платформы для костимуляции, новые конструкции car и другие улучшения для адаптивной клеточной терапии |
-
2020
- 2020-03-30 MX MX2021012336A patent/MX2021012336A/es unknown
- 2020-03-30 WO PCT/US2020/025643 patent/WO2020210067A1/en unknown
- 2020-03-30 KR KR1020217034403A patent/KR20210150432A/ko unknown
- 2020-03-30 CA CA3132202A patent/CA3132202A1/en active Pending
- 2020-03-30 US US17/593,087 patent/US20220184127A1/en active Pending
- 2020-03-30 JP JP2021559535A patent/JP2022526420A/ja active Pending
- 2020-03-30 SG SG11202108759S patent/SG11202108759SA/en unknown
- 2020-03-30 EP EP20788157.4A patent/EP3952888A1/en not_active Withdrawn
- 2020-03-30 CN CN202080027518.8A patent/CN113795262A/zh active Pending
- 2020-03-30 BR BR112021016272A patent/BR112021016272A2/pt not_active Application Discontinuation
- 2020-03-30 AU AU2020271012A patent/AU2020271012A1/en not_active Abandoned
-
2021
- 2021-10-05 IL IL286984A patent/IL286984A/en unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210150432A (ko) | 2021-12-10 |
CN113795262A (zh) | 2021-12-14 |
IL286984A (en) | 2021-12-01 |
CA3132202A1 (en) | 2020-10-15 |
BR112021016272A2 (pt) | 2021-11-09 |
EP3952888A1 (en) | 2022-02-16 |
JP2022526420A (ja) | 2022-05-24 |
WO2020210067A1 (en) | 2020-10-15 |
US20220184127A1 (en) | 2022-06-16 |
SG11202108759SA (en) | 2021-10-28 |
AU2020271012A1 (en) | 2021-09-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021012336A (es) | Receptores de antigeno quimerico anti-dll3 humanizados y usos de los mismos. | |
MX2019003886A (es) | Receptores de antigenos quimericos para el tratamiento del cancer. | |
PH12020552138A1 (en) | Bcma chimeric antigen receptors and uses thereof | |
WO2015142675A3 (en) | Treatment of cancer using chimeric antigen receptor | |
PH12020551391A1 (en) | Antibodies against signal-regulatory protein alpha and methods of use | |
PH12020551160A1 (en) | Chimeric antigen receptors targeting cd70 | |
MY190711A (en) | Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor | |
EP4219689A3 (en) | Immune effector cell therapies with enhanced efficacy | |
MX2017001013A (es) | Tratamiento de cáncer usando un receptor quimérico de antígeno cll-1. | |
MX2020012927A (es) | Diversos dominios de enlace de antigenos, nuevas plataformas y otras mejoras para terapia celular. | |
AU2014236098A8 (en) | Treatment of cancer using humanized anti-CD19 chimeric antigen receptor | |
EA201992469A1 (ru) | Антигенспецифические иммунные эффекторные клетки | |
WO2020016662A3 (en) | Antibodies specific to trophoblast antigen 2 (trop2) | |
MY181834A (en) | Treatment of cancer using humanized anti-bcma chimeric antigen receptor | |
MX2021011887A (es) | Receptores de antigeno quimerico humanizados anti-claudin 18.2 y usos de los mismos. | |
MX2019000643A (es) | Receptores de antigenos quimericos y metodos de uso. | |
MX2017001008A (es) | Tratamiento de cancer utilizando un receptor quimerico de antigeno cd33. | |
MX2016008076A (es) | Receptores quimericos de antigeno de mesotelina humana y uso de los mismos. | |
PE20110593A1 (es) | Anticuerpos multiespecificos | |
MX2019002903A (es) | Receptores de antigeno quimerico que comprenden dominios de tipo iii de fibronectina especificos del bcma y usos de estos. | |
PH12020551134A1 (en) | Fc variants with enhanced binding to fcrn and prolonged half-life | |
WO2019112347A3 (ko) | 악성 b 세포를 특이적으로 인지하는 항체 또는 그의 항원 결합 단편, 이를 포함하는 키메라 항원 수용체 및 이의 용도 | |
WO2014016702A3 (en) | Humanized forms of monoclonal antibodies to human gnrh receptor | |
MX2021012488A (es) | Receptores de antigeno quimerico del receptor 1 anti-folato humanizado y usos de los mismos. | |
MX2020000595A (es) | Regiones de unión al antígeno contra dominios de fibronectina tipo iii y métodos para su uso. |